It’s a make-or-break moment for Verily, as the sprawling Google offshoot rapidly accelerates its strategy to take its most promising products and turn them into tools that not only transform medicine, but also drive profit.
In recent months, the company has assembled an all-star team of executives to bring its software and data tools to the market. They include Amy Abernethy, formerly a top data and informatics leader at the Food and Drug Administration, and Stephen Gillett, previously an executive at Best Buy and Starbucks who is now Verily’s chief operating officer. Since its founding seven years ago, the company has functioned essentially as a think tank with an array of disparate initiatives. Now, its new C-suite will be put to the test as it tries to turn Verily into a sustainable business capable of delivering on its core promises.
“Now’s the moment to take the company forward,” Jess Mega, a founder of Verily and its chief medical and scientific officer, told STAT. “We’re now at a stage where we can really scale and commercialize these tools in an end-to-end way.”
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect